Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Bone marrow fibrosis (BMF) is a poor prognostic indicator in myelodysplastic syndromes (MDS).
• The prognostic impact of BMF, especially severe BMF, within current MDS risk stratification systems requires further investigation.

Purpose of the Study:

• To investigate the association between BMF in MDS and patient survival outcomes.
• To explore the spectrum of somatic gene mutations in MDS patients with varying degrees of BMF.

Main Methods:

• Retrospective analysis of 2624 MDS patients categorized by BMF grade (0-2 vs. 3).
• Comparison of somatic gene mutations using next-generation sequencing data between BMF groups.
• Evaluation of survival outcomes and treatment responses.

Main Results:

• Severe (grade 3) BMF was independently associated with worse overall survival (HR=1.6).
• Patients with severe BMF had higher-risk classifications (MDS-EB, higher IPSS-R) and more frequent TP53 and SETBP1 mutations.
• No significant difference in response to hypomethylating agents or lenalidomide was observed based on BMF grade.

Conclusions:

• Grade 3 BMF is an independent predictor of reduced survival in MDS patients.
• TP53 and SETBP1 mutations are more prevalent in MDS with severe fibrosis.
• BMF severity does not influence the efficacy of standard MDS therapies like hypomethylating agents or lenalidomide.